Mismatch repair genes MSH2 and MLH1 are the two major genes implicated in hereditary nonpolyposis colorectal cancer. For the past years, we have successfully searched for mutations in both genes in affected Portuguese families, by SSCP and DNA sequencing analysis but because of the advantages that DHPLC offers, we have established conditions in our laboratory to use this new method. While screening for mutations by both methods, in 35 individuals belonging to HNPCC Portuguese families, 4 novel MLH1 mutations (c.307-1G>C; c.1023delG [p.R341fsX366]; c.2154_2155delCA [p.H718fsX721], c.2154_2155dupCA [p.I719fsX782]), an unclassified variant (c.-28A>T) and one silent MSH2 polymorphism (c.2766T>C) have been identified.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/humu.9192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Germline structural variant as the cause of Lynch Syndrome in a family from Ecuador.
NPJ Genom Med
January 2025
Gastroenterology Deparment, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain.
Colorectal cancer (CRC) is one of the most common cancers worldwide. Lynch Syndrome (LS) is the most common form of hereditary CRC and it is caused by germline defects in the DNA-mismatch repair (MMR) pathway. It is of extreme importance for affected LS patients and their relatives to identify the germline causative alteration to provide intensified surveillance to those at risk and allow early diagnosis and cancer prevention.
View Article and Find Full Text PDFMELATONIN ENHANCES TEMOZOLOMIDE-INDUCED APOPTOSIS IN GLIOBLASTOMA AND NEUROBLASTOMA CELLS.
Exp Oncol
October 2024
Department of Medical Biology, Faculty of Medicine, Trakya University, Edirne, Turkey.
Article Synopsis
- The study investigates the effects of melatonin (MEL) combined with temozolomide (TMZ) on glioblastoma and neuroblastoma cancer cell lines, aiming to understand how this combination affects cell viability and resistance.
- Results reveal that the MEL and TMZ combination significantly decreases cancer cell viability and increases apoptosis compared to other treatments, highlighting a potential strategy to counteract drug resistance in these cancers.
- The findings suggest that this combination therapy upregulates genes involved in antioxidant defense and DNA repair, indicating a possible mechanism through which MEL enhances the efficacy of TMZ.
Novel MLH1 nonsense variant in a patient with suspected Lynch syndrome.
Hum Genome Var
September 2024
Risk Assessment Unit, Aichi Cancer Center Hospital, Nagoya, Japan.
Article Synopsis
- Loss-of-function germline variants in the MLH1 gene are linked to Lynch syndrome, a hereditary condition that increases cancer risk.
- A 43-year-old male patient was diagnosed with cecal and transverse colon adenocarcinomas, which fit the revised Bethesda guidelines for Lynch syndrome assessment.
- Genetic testing revealed a novel pathogenic variant in the MLH1 gene, confirming the diagnosis of Lynch syndrome for this patient.
Lynch Syndrome-associated Genomic Variants.
J Gastrointestin Liver Dis
September 2024
Dept. of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, Bucharest; Dept. of Obstetrics and Gynecology, Alessandrescu-Rusescu National Institute of Mother and Child Health, Bucharest, Romania.
Article Synopsis
- Lynch Syndrome, linked to mutations in mismatch repair (MMR) genes, is a major factor in both colorectal and endometrial cancers, but the genetic details of these connections are not fully understood.
- This study utilized whole exome sequencing from 13 patients with Lynch syndrome-associated endometrial cancer to compare germline and somatic mutations, identifying thousands of variants and confirming the role of specific pathogenic mutations.
- Findings include shared mutations in MMR genes and new somatic mutations in the PIK3CA and PTEN genes, suggesting potential targeted treatment approaches for these cancers.
Development of a Novel Protocol for Germline Testing in Pancreatic Cancer.
Ann Surg Oncol
November 2024
Division of Surgical Oncology, Department of Surgery, University of Kentucky, Lexington, KY, USA.
Background: Guidelines now recommend universal germline genetic testing (GGT) for all pancreatic ductal adenocarcinoma (PDAC) patients. Testing provides information on actionable pathogenic variants and guides management of patients and family. Since traditional genetic counseling (GC) models are time-intensive and GC resources are sparse, new approaches are needed to comply with guidelines without overwhelming available resources.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!